Agile Therapeutics (AGRX) Misses Q2 EPS by 301c

Agile Therapeutics (NASDAQ: AGRX) reported Q2 EPS of ($3.10), $3.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $3.45 million.

For earnings history and earnings-related data on Agile Therapeutics (AGRX) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Performance Food Group (PFGC) Misses Q4 EPS by 1c ; Offers Guidance
• Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 6c